{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:12:30Z","timestamp":1784236350706,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["ZMVI1-2520AUK700"],"award-info":[{"award-number":["ZMVI1-2520AUK700"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Sex Behav"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human immunodeficiency virus pre-exposure prophylaxis (PrEP) is considered as an effective protection against a human immunodeficiency virus (HIV) infection. However, it is still unclear, how PrEP use is associated with the incidence of sexually transmitted infections (STI) other than HIV. PrEP became reimbursable in Germany from September 1, 2019 for persons with statutory health insurance (SHI). With the EvE-PrEP study, the Federal Ministry of Health commissioned the evaluation of the effects of the new reimbursement situation in Germany. In the presented module of the EvE-PrEP study, routine data from three large German SHI funds were analyzed in anonymized form for the period January 1, 2019 to March 31, 2020. Data were analyzed regarding: Characteristics and adherence of PrEP users, treatment success of PrEP, and changes in STI incidence rates before and since PrEP use. The cooperating SHI funds collectively covered about 52% of the overall population in Germany in 2019. A total of 7102 persons with PrEP use were included into the analysis. These were predominantly male (99%), on average 37.4\u00a0years old and a high proportion of persons lived in large cities. The average quotient of PrEP daily defined doses and assumed days on PrEP was 87%. The average STI rates normalized per 100 person-years at individual level pre PrEP did not statistically significant differ compared to since PrEP (chlamydia: 17.5 vs. 17.6, gonococcal infection: 29.1 vs. 30.7, and syphilis: 14.6 vs.13.6). A large data set was used to evaluate the introduction of PrEP as a SHI benefit in Germany. A potentially suspected increase in bacterial STI incidence rates was not found. A rather high average adherence rate was observed. The very high proportion of men and people from the largest German cities among PrEP users is striking. These results could indicate barriers to PrEP access for people at risk of HIV, especially if they are women or people living in less urban areas.<\/jats:p>","DOI":"10.1007\/s10508-024-02922-5","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:02:08Z","timestamp":1722970928000},"page":"3663-3672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Routine Data Analysis of HIV Pre-Exposure Prophylaxis Use and Rates of Sexually Transmitted Infections Since Coverage of HIV Pre-Exposure Prophylaxis by the Statutory Health Insurance in Germany"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-5841","authenticated-orcid":false,"given":"Frederik","family":"Valbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Dr\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Friebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"9","key":"2922_CR1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jiph.2022.07.012","volume":"15","author":"P Ahaus","year":"2022","unstructured":"Ahaus, P., Schmidt, A. J., Skaletz-Rorowski, A., Uhrmacher, M., Serova, K., Kayser, A., & Potthoff, A. (2022). Changes in the user profiles of HIV pre-exposure prophylaxis (PrEP) before and after PrEP reimbursement. Journal of Infection and Public Health, 15(9), 955\u2013960. https:\/\/doi.org\/10.1016\/j.jiph.2022.07.012","journal-title":"Journal of Infection and Public Health"},{"issue":"5","key":"2922_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., & Celum, C. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine, 367(5), 399\u2013410. https:\/\/doi.org\/10.1056\/NEJMoa1108524","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"2922_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1024\/0301-1526\/a000589","volume":"46","author":"C-A Behrendt","year":"2017","unstructured":"Behrendt, C.-A., Heidemann, F., Rie\u00df, H. C., Stoberock, K., & Debus, S. E. (2017). Registry and health insurance claims data in vascular research and quality improvement. Vasa, 46(1), 11\u201315. https:\/\/doi.org\/10.1024\/0301-1526\/a000589","journal-title":"Vasa"},{"issue":"6","key":"2922_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/sextrans-2017-053377","volume":"94","author":"MR Beymer","year":"2018","unstructured":"Beymer, M. R., DeVost, M. A., Weiss, R. E., Dierst-Davies, R., Shover, C. L., Landovitz, R. J., & Bolan, R. K. (2018). Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California. Sexually Transmitted Infections, 94(6), 457\u2013462. https:\/\/doi.org\/10.1136\/sextrans-2017-053377","journal-title":"California. Sexually Transmitted Infections"},{"issue":"1","key":"2922_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(17)30540-6","volume":"18","author":"V Cambiano","year":"2018","unstructured":"Cambiano, V., Miners, A., Dunn, D., McCormack, S., Ong, K. J., Gill, O. N., & Phillips, A. N. (2018). Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: A modelling study and health economic evaluation. The Lancet Infectious Diseases, 18(1), 85\u201394. https:\/\/doi.org\/10.1016\/S1473-3099(17)30540-6","journal-title":"The Lancet Infectious Diseases"},{"key":"2922_CR8","unstructured":"European Medicines Agency. (2016). First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU: Truvada to enhance existing HIV prevention strategies. Retrieved from https:\/\/www.ema.europa.eu\/en\/news\/first-medicine-hiv-pre-exposureprophylaxis-recommended-approvaleu#:~:text=Truvada%20is%20the%20first%20medicine,also%20other%20sexually%20transmitted%20infections"},{"issue":"3","key":"2922_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.amepre.2020.10.021","volume":"60","author":"B Fayaz Farkhad","year":"2021","unstructured":"Fayaz Farkhad, B., Holtgrave, D. R., & Albarrac\u00edn, D. (2021). Effect of medicaid expansions on HIV diagnoses and pre-exposure prophylaxis use. American Journal of Preventive Medicine, 60(3), 335\u2013342. https:\/\/doi.org\/10.1016\/j.amepre.2020.10.021","journal-title":"American Journal of Preventive Medicine"},{"key":"2922_CR10","unstructured":"Federal Ministry of Health. (2019). Mitgliederstatistik KM6: Jahresdurchschnitt 2019. Retrieved from https:\/\/www.bundesgesundheitsministerium.de\/themen\/krankenversicherung\/zahlen-und-fakten-zur-krankenversicherung\/mitglieder-und-versicherte.html"},{"key":"2922_CR5","unstructured":"Federal Ministry of Justice. (2019). Bundesgesetzblatt 2019 Teil I Nr. 18. Retrieved from http:\/\/www.bgbl.de\/xaver\/bgbl\/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s0646.pdf"},{"key":"2922_CR11","unstructured":"Federal Statistical Office of Germany. (2023, January 10). Bev\u00f6lkerung: Deutschland, Stichtag 31.12.2019. Retrieved from https:\/\/www-genesis.destatis.de\/genesis\/online?operation=abruftabelleBearbeiten&levelindex=1&levelid=1673360440445&auswahloperation=abruftabelleAuspraegungAuswaehlen&auswahlverzeichnis=ordnungsstruktur&auswahlziel=werteabruf&code=12411-0001&auswahltext=&werteabruf=Werteabruf#abreadcrumb"},{"issue":"12","key":"2922_CR12","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R., O\u2019Reilly, K. R., Koechlin, F. M., & Grant, R. M. (2016). Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS, 30(12), 1973\u20131983. https:\/\/doi.org\/10.1097\/QAD.0000000000001145","journal-title":"AIDS (london, England)"},{"issue":"1","key":"2922_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12913-018-3080-3","volume":"18","author":"FM Gansen","year":"2018","unstructured":"Gansen, F. M. (2018). Health economic evaluations based on routine data in Germany: A systematic review. BMC Health Services Research, 18(1), 268. https:\/\/doi.org\/10.1186\/s12913-018-3080-3","journal-title":"BMC Health Services Research"},{"issue":"27","key":"2922_CR14","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"2010","author":"RM Grant","year":"2010","unstructured":"Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., & Chariyalertsak, S. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 2010(27), 2587\u20132599. https:\/\/doi.org\/10.1056\/NEJMoa1011205","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"2922_CR15","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1007\/s00103-008-0646-y","volume":"51","author":"F Hoffmann","year":"2008","unstructured":"Hoffmann, F., Andersohn, F., Giersiepen, K., Scharnetzky, E., & Garbe, E. (2008). Validierung von Sekund\u00e4rdaten Grenzen und M\u00f6glichkeiten. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 51(10), 1118\u20131126. https:\/\/doi.org\/10.1007\/s00103-008-0646-y","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"issue":"5","key":"2922_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/cid\/cix439","volume":"65","author":"SM Jenness","year":"2017","unstructured":"Jenness, S. M., Weiss, K. M., Goodreau, S. M., Gift, T., Chesson, H., Hoover, K. W., & Rosenberg, E. S. (2017). Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: A modeling study. Clinical Infectious Diseases, 65(5), 712\u2013718. https:\/\/doi.org\/10.1093\/cid\/cix439","journal-title":"Clinical Infectious Diseases"},{"key":"2922_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-022-01699-y","author":"U Marcus","year":"2022","unstructured":"Marcus, U., Schmidt, D., Schink, S. B., & Koppe, U. (2022). Analysis of HIV pre-exposure prophylaxis (PrEP) needs and PrEP use in Germany among men who have sex with men. Journal of Public Health. https:\/\/doi.org\/10.1007\/s10389-022-01699-y","journal-title":"Journal of Public Health"},{"issue":"10013","key":"2922_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack, S., Dunn, D., Desai, M., Dolling, D., Gafos, M., Gilson, R., & Gil, O. N. (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet, 387(10013), 53\u201360.","journal-title":"The Lancet"},{"issue":"12","key":"2922_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30806","volume":"3","author":"H McManus","year":"2020","unstructured":"McManus, H., Grulich, A. E., Amin, J., Selvey, C., Vickers, T., Bavinton, B., & Guy, R. (2020). Comparison of trends in rates of sexually transmitted infections before vs after initiation of HIV preexposure prophylaxis among men who have sex with men. JAMA Network Open, 3(12), e2030806. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.30806","journal-title":"JAMA Network Open"},{"issue":"9","key":"2922_CR20","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1016\/S2352-3018(17)30089-9","volume":"4","author":"J-M Molina","year":"2017","unstructured":"Molina, J.-M., Charreau, I. Isabelle., Spire, B. Bruno., Cotte, L., Chas, J., Capitant, C. Catherine., & Rabian, C. (2017). Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: An observational cohort study. The Lancet HIV, 4(9), e402\u2013e410. https:\/\/doi.org\/10.1016\/S2352-3018(17)30089-9","journal-title":"The Lancet HIV"},{"key":"2922_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.zefq.2016.03.016","volume":"115\u2013116","author":"C M\u00fcnch","year":"2016","unstructured":"M\u00fcnch, C., Gottschall, M., H\u00fcbsch, G., K\u00f6berlein-Neu, J., Sch\u00fcbel, J., Bergmann, A., & Voigt, K. (2016). Qualit\u00e4t der haus\u00e4rztlichen Diagnosedokumentation in Patientenakten\u2014Eine Analyse am Beispiel von Schilddr\u00fcsenerkrankungen. Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t Im Gesundheitswesen, 115\u2013116, 56\u201362.","journal-title":"Zeitschrift F\u00fcr Evidenz, Fortbildung und Qualit\u00e4t Im Gesundheitswesen."},{"key":"2922_CR6","unstructured":"National Association of Statutory Health Insurance Physicians, National Association of Statutory Health Insurance Funds. (2019). Anlage 33 zum Bundesmantelvertrag-\u00c4rzte. Retrieved from https:\/\/www.gkvspitzenverband.de\/media\/dokumente\/krankenversicherung_1\/aerztliche_versorgung\/bundesmantelvertrag_1\/bmv_anlagen\/BMVAe_Anlage_33_PreP_24-7-2019.pdf"},{"issue":"4","key":"2922_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/QAD.0000000000001718","volume":"32","author":"V-K Nguyen","year":"2018","unstructured":"Nguyen, V.-K., Greenwald, Z. R., Trottier, H., Cadieux, M., Goyette, A., Beauchemin, M., & Thomas, R. (2018). Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. AIDS, 32(4), 523\u2013530. https:\/\/doi.org\/10.1097\/QAD.0000000000001718","journal-title":"AIDS (london, England)"},{"issue":"4","key":"2922_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/QAD.0000000000002469","volume":"34","author":"M Reitsema","year":"2020","unstructured":"Reitsema, M., van Hoek, A. J., van der Loeff, M. S., Hoornenborg, E., van Sighem, A., Wallinga, J., & Xiridou, M. (2020). Preexposure prophylaxis for men who have sex with men in the Netherlands: Impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness. AIDS, 34(4), 621\u2013630. https:\/\/doi.org\/10.1097\/QAD.0000000000002469","journal-title":"AIDS (london, England)"},{"key":"2922_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.21203\/rs.3.rs-1201597\/v1","volume":"51","author":"The NEPOS Study Group","year":"2023","unstructured":"Schmidt, D., Kollan, C., Bartmeyer, B., Bremer, V., Schikowski, T., Friebe, M., & The NEPOS Study Group. (2023). Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. Infection, 51, 655\u2013678. https:\/\/doi.org\/10.21203\/rs.3.rs-1201597\/v1","journal-title":"Infection"},{"key":"2922_CR25","first-page":"3","volume":"6","author":"D Schmidt","year":"2021","unstructured":"Schmidt, D., Merbach, M., Friebe, M., Hanhoff, N., Rosenberg, R., & Schewe, K. (2021). Wissenschaftliche Begleitung und Evaluation der HIV-Pr\u00e4expositionsprophylaxe (PrEP) als Leistung der gesetzlichen Krankenversicherung\u2014das Projekt EvE-PrEP in Zeiten der SARS-CoV-2-Pandemie. Epidemiologisches Bulletin., 6, 3\u201312.","journal-title":"Epidemiologisches Bulletin."},{"key":"2922_CR26","doi-asserted-by":"publisher","unstructured":"Schubert, I., K\u00f6ster, I., K\u00fcpper-Nybelen, J., & Ihle, P. (2008). Versorgungsforschung mit GKV-Routinedaten. Nutzungsm\u00f6glichkeiten versichertenbezogener Krankenkassendaten f\u00fcr Fragestellungen der Versorgungsforschung [Health services research based on routine data generated by the SHI. Potential uses of health insurance fund data in health services research]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 51(10), 1095\u20131105. https:\/\/doi.org\/10.1007\/s00103-008-0644-0","DOI":"10.1007\/s00103-008-0644-0"},{"key":"2922_CR27","doi-asserted-by":"publisher","unstructured":"Schubert, I., Ihle, P., & K\u00f6ster, I. (2010). Interne Validierung von Diagnosen in GKV-Routinedaten: Konzeption mit Beispielen und Falldefinition [Internal confirmation of diagnoses in routine statutory health insurance data: Concepts with examples and case definitions]. Gesundheitswesen, 72(6), 316\u2013322. https:\/\/doi.org\/10.1055\/s-0030-1249688","DOI":"10.1055\/s-0030-1249688"},{"issue":"9","key":"2922_CR28","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/cid\/ciz552","volume":"70","author":"JA Serpa","year":"2020","unstructured":"Serpa, J. A., Huynh, G. N., Nickell, J. B., & Miao, H. (2020). Human Immunodeficiency virus pre-exposure prophylaxis and increased incidence of sexually transmitted infections in the United States. Clinical Infectious Diseases, 70(9), 1884\u20131890. https:\/\/doi.org\/10.1093\/cid\/ciz552","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"2922_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s15010-015-0850-2","volume":"44","author":"CD Spinner","year":"2016","unstructured":"Spinner, C. D., Boesecke, C., Zink, A., Jessen, H., Stellbrink, H.-J., Rockstroh, J. K., & Esser, S. (2016). HIV pre-exposure prophylaxis (PrEP): A review of current knowledge of oral systemic HIV PrEP in humans. Infection, 44(2), 151\u2013158. https:\/\/doi.org\/10.1007\/s15010-015-0850-2","journal-title":"Infection"},{"key":"2922_CR30","doi-asserted-by":"publisher","unstructured":"Streeck, H., Jansen, K., Crowell, T. A., Esber, A., Jessen, H. K., Cordes, C., Michael, N. L. (2022). HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019. Euro Surveillance, 27(14). https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.14.2100591","DOI":"10.2807\/1560-7917.ES.2022.27.14.2100591"},{"key":"2922_CR31","doi-asserted-by":"publisher","unstructured":"Tan, D. H. S., Dashwood, T. M., Wilton, J., Kroch, A., Gomes, T., & Martins, D. (2021). Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: A population-based analysis of projected pharmacy data (2015\u20132018). Canadian Journal of Public Health, 112(1), 89\u201396. https:\/\/doi.org\/10.17269\/s41997-020-00332-3","DOI":"10.17269\/s41997-020-00332-3"},{"issue":"5","key":"2922_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., & Brooks, J. T. (2012). Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine, 367(5), 423\u2013434. https:\/\/doi.org\/10.1056\/NEJMoa1110711","journal-title":"The New England Journal of Medicine"},{"issue":"14","key":"2922_CR33","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/jama.2019.2947","volume":"321","author":"MW Traeger","year":"2019","unstructured":"Traeger, M. W., Cornelisse, V. J., Asselin, J., Price, B., Roth, N. J., Willcox, J., & Wright, E. J. (2019). Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. Journal of the American Medical Association, 321(14), 1380\u20131390. https:\/\/doi.org\/10.1001\/jama.2019.2947","journal-title":"JAMA"},{"key":"2922_CR34","doi-asserted-by":"publisher","unstructured":"Van de Vijver, D. A. M. C., Richter, A.\u2011K., Boucher, C. A. B., Gunsenheimer-Bartmeyer, B., Kollan, C., Nichols, B. E., Neumann, A. (2019). Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. Euro Surveillance, 24(7). https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.7.1800398","DOI":"10.2807\/1560-7917.ES.2019.24.7.1800398"},{"issue":"12","key":"2922_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208107","volume":"13","author":"RN Werner","year":"2018","unstructured":"Werner, R. N., Gaskins, M., Nast, A., & Dressler, C. (2018). Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection\u2014A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS ONE, 13(12), e0208107. https:\/\/doi.org\/10.1371\/journal.pone.0208107","journal-title":"PLoS ONE"},{"issue":"12","key":"2922_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226209","volume":"14","author":"RN Werner","year":"2019","unstructured":"Werner, R. N., Gaskins, M., Nast, A., & Dressler, C. (2019). Correction: Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection\u2014A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS ONE, 14(12), e0226209. https:\/\/doi.org\/10.1371\/journal.pone.0226209","journal-title":"PLoS ONE"}],"container-title":["Archives of Sexual Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10508-024-02922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10508-024-02922-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10508-024-02922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T18:09:14Z","timestamp":1726078154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10508-024-02922-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1007\/s10508-024-02922-5","relation":{},"ISSN":["0004-0002","1573-2800"],"issn-type":[{"value":"0004-0002","type":"print"},{"value":"1573-2800","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was funded by the German Federal Ministry of Health. An ethics vote was not necessary because only anonymous data were analyzed retrospectively. The transfer of initially pseudonymized routine data of insured persons of Techniker Krankenkasse and of DAK Gesundheit was applied for and approved at the German Federal Office for Social Security (original institution name: \u201cBundesamt f\u00fcr Soziale Sicherung\u201d). This was not necessary for the data from the AOK\u2014Die Gesundheitskasse, as these were only made available in anonymized form from the beginning.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable (only anonymized secondary data).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}